Department of pediatrics, National Social Insurance Fund Hospital, centre hospitalier d'ESSOS, PO Box 5777, Yaoundé, Cameroon.
École polytechnique Yaoundé, Specialized Masters in Mathematics, Yaoundé, Cameroon.
Med Mal Infect. 2017 Feb;47(1):32-37. doi: 10.1016/j.medmal.2016.07.003. Epub 2016 Sep 5.
The mortality rate of HIV-infected children can be reversed under highly active antiretroviral therapy (HAART). The impact of HAART on the mortality of HIV-infected children in Cameroon has not been extensively documented. We aimed to measure the mortality rate of HIV-infected children under HAART and to identify predictive factors of mortality.
Retrospective cohort study of 221 children initiated on HAART from 2005 to 2009 and followed-up until 2013. Survival data was analyzed using Kaplan Meier method and Cox regression model to identify independent predictors of child mortality on HAART.
Overall, 9.9% of children (n=22) died over a follow-up period of 755 child-years (mortality of 2.9 per 100 child-years); 70% of deaths occurred during the first six months of HAART. The probability of survival after four years of treatment was 88.7% (95% CI=[84.2-93.3]). During the multivariate analysis of baseline variables, we observed that the WHO clinical stages III and IV (HR: 3.55 [1.09-13.6] and HR: 7.7 [3.07-31.2]) and age≤1year at HAART initiation were independently associated with death (HR: 2.1 [1.01-5.08]). Neither orphanhood, baseline CD4 count or hemoglobin level nor low nutritional status predicted death in this cohort.
The mortality of children receiving HAART was low after five years of follow-up and it was strongly associated with WHO stages III and IV and a younger age at treatment initiation.
在高效抗逆转录病毒治疗(HAART)下,HIV 感染儿童的死亡率可以逆转。HAART 对喀麦隆 HIV 感染儿童死亡率的影响尚未得到广泛记录。我们旨在测量接受 HAART 的 HIV 感染儿童的死亡率,并确定死亡率的预测因素。
这是一项 2005 年至 2009 年期间开始接受 HAART 的 221 名儿童的回顾性队列研究,并随访至 2013 年。使用 Kaplan-Meier 方法和 Cox 回归模型分析生存数据,以确定接受 HAART 的儿童死亡的独立预测因素。
总体而言,22 名儿童(n=22)在 755 个儿童年的随访期间死亡(死亡率为 2.9/100 儿童年);70%的死亡发生在 HAART 的前 6 个月。治疗四年后的生存率为 88.7%(95%CI=[84.2-93.3])。在对基线变量的多变量分析中,我们观察到 WHO 临床分期 III 和 IV(HR:3.55 [1.09-13.6]和 HR:7.7 [3.07-31.2])和 HAART 开始时年龄≤1 岁与死亡独立相关(HR:2.1 [1.01-5.08])。在本队列中,孤儿状态、基线 CD4 计数或血红蛋白水平以及低营养状况均与死亡无关。
接受 HAART 治疗五年后的儿童死亡率较低,与 WHO 分期 III 和 IV 以及治疗开始时年龄较小密切相关。